Core Viewpoint - United Therapeutics reported a revenue of $798.6 million for the quarter ended June 2025, reflecting an 11.7% increase year-over-year, and an EPS of $6.41, up from $5.85 in the previous year [1] Revenue Performance - U.S. revenues reached $759.8 million, exceeding the average estimate of $749.74 million by analysts, marking a 12.5% increase year-over-year [4] - Revenues from the Rest-of-World segment were $38.8 million, slightly above the average estimate of $33.98 million, but represented a 2.3% decline year-over-year [4] - Tyvaso generated $455.3 million in U.S. revenues, slightly above the average estimate of $452.61 million [4] - Unituxin in the U.S. brought in $55.4 million, surpassing the average estimate of $53.07 million [4] - Adcirca revenues were $6.5 million, exceeding the average estimate of $4.81 million, reflecting a 14% increase year-over-year [4] - Orenitram generated $123.9 million, above the average estimate of $118.65 million, with a 15.7% year-over-year increase [4] - Tyvaso reported $469.6 million, slightly below the average estimate of $473.16 million, but still a 17.9% increase year-over-year [4] - Remodulin revenues were $134.7 million, below the average estimate of $137.99 million, representing an 8.6% decline year-over-year [4] - Unituxin generated $58.4 million, exceeding the average estimate of $55.58 million, with a 13% year-over-year increase [4] - Tyvaso DPI revenues were $315.2 million, in line with the average estimate of $313.48 million [4] - Nebulized Tyvaso brought in $154.4 million, slightly below the average estimate of $154.53 million [4] - Other products generated $5.5 million, exceeding the average estimate of $4.95 million, reflecting a 12.2% year-over-year increase [4] Stock Performance - United Therapeutics shares returned +2.3% over the past month, compared to the Zacks S&P 500 composite's +3.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

CHONGQING, CHINA - JULY 29: In this photo illustration, a person holds a smartphone displaying the ... More logo of Bristol Myers Squibb Company (NYSE: BMY), a global biopharmaceutical firm focused on oncology, immunology, and cardiovascular diseases, with the company's purple hand-shaped branding visible in the background, on July 29, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images) Getty Images Bristol Myers Squibb (NYSE:BMY) is scheduled to release its earnings report on Thursday, ...

Group 1 - Amedisys reported $621.86 million in revenue for the quarter ended June 2025, a year-over-year increase of 5.2% [1] - The EPS for the same period was $1.54, compared to $1.32 a year ago, representing a surprise of +10.79% over the consensus estimate of $1.39 [1] - The reported revenue exceeded the Zacks Consensus Estimate of $609.65 million by +2% [1] Group 2 - Key metrics for Amedisys include Net Service Revenue for High Acuity Care at $10.7 million, a +9.2% change year-over-year [4] - Net Service Revenue for Hospice was reported at $215 million, reflecting a +5.4% year-over-year change [4] - Net Service Revenue for Home Health was $396.2 million, representing a +5% increase compared to the previous year [4] Group 3 - Amedisys shares have returned -1.5% over the past month, underperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance in the near term [3]

Core Insights - Sensata reported revenue of $943.38 million for the quarter ended June 2025, reflecting a year-over-year decline of 8.9% and an EPS of $0.87 compared to $0.93 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $933.26 million by 1.09%, while the EPS surpassed the consensus estimate of $0.84 by 3.57% [1] Revenue Breakdown - Net Revenue from Sensing Solutions was $291.16 million, exceeding the four-analyst average estimate of $276.84 million, with a year-over-year increase of 8.6% [4] - Net Revenue from Performance Sensing was $652.23 million, slightly below the four-analyst average estimate of $656.62 million, showing a year-over-year decline of 9.9% [4] Operating Income - Operating income for Sensing Solutions was reported at $88.04 million, surpassing the three-analyst average estimate of $83.93 million [4] - Operating income for Performance Sensing was $146.88 million, also exceeding the three-analyst average estimate of $144.84 million [4] Stock Performance - Sensata's shares have returned +9.4% over the past month, outperforming the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Mondelez (MDLZ) reported $8.98 billion in revenue for the quarter ended June 2025, representing a year-over- year increase of 7.7%. EPS of $0.73 for the same period compares to $0.86 a year ago. Here is how Mondelez performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: View all Key Company Metrics for Mondelez here>>> While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare t ...

For the quarter ended June 2025, Varonis Systems (VRNS) reported revenue of $152.16 million, up 16.7% over the same period last year. EPS came in at $0.03, compared to $0.05 in the year-ago quarter. View all Key Company Metrics for Varonis here>>> Shares of Varonis have returned +7.2% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Annual Recurring Revenue ...

Core Insights - Electronic Arts (EA) reported revenue of $1.3 billion for the quarter ended June 2025, reflecting a year-over-year increase of 2.9% and a surprise of +4.65% over the Zacks Consensus Estimate of $1.24 billion [1] - The earnings per share (EPS) for the quarter was $0.25, a decrease from $0.52 in the same quarter last year, with an EPS surprise of +150% compared to the consensus estimate of $0.10 [1] Financial Performance Metrics - Net Bookings for EA were reported at $1.3 billion, exceeding the average estimate of $1.24 billion from seven analysts [4] - Net revenue from Live services and other (Non-GAAP Net Bookings) was $1.08 billion, slightly above the three-analyst average estimate of $1.03 billion, showing a year-over-year decline of -0.9% [4] - Net revenue from Full game downloads (Non-GAAP Net Bookings) was $147 million, surpassing the two-analyst average estimate of $139.3 million, with a year-over-year increase of +2.8% [4] - Net revenue from Full game packaged goods (Non-GAAP Net Bookings) was $27 million, exceeding the two-analyst average estimate of $24.02 million, representing a year-over-year increase of +8% [4] Stock Performance - EA's shares have returned -4.8% over the past month, contrasting with the Zacks S&P 500 composite's +3.6% change [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]

Core Insights - NMI Holdings (NMIH) reported a revenue of $173.78 million for the quarter ended June 2025, marking a year-over-year increase of 7.2% and exceeding the Zacks Consensus Estimate by 1.87% [1] - The earnings per share (EPS) for the same period was $1.22, slightly up from $1.20 a year ago, with an EPS surprise of 5.17% compared to the consensus estimate of $1.16 [1] Financial Performance Metrics - Insurance-in-force (IIF) reached $214.65 billion, surpassing the average estimate of $211.73 billion from three analysts [4] - Risk-in-force (RIF) was reported at $57.5 billion, exceeding the average estimate of $55.61 billion from three analysts [4] - The combined ratio stood at 28.8%, better than the three-analyst average estimate of 30% [4] - The loss ratio was 9%, slightly better than the average estimate of 9.1% [4] - The expense ratio was reported at 19.8%, lower than the three-analyst average estimate of 20.9% [4] - Net investment income was $24.95 million, exceeding the average estimate of $23.11 million and reflecting a year-over-year change of 20.6% [4] - Net premiums earned amounted to $149.07 million, surpassing the average estimate of $147.25 million with a year-over-year increase of 5.6% [4] - Other revenues were reported at $0.16 million, below the average estimate of $0.23 million, showing a significant year-over-year decline of 38.4% [4] Stock Performance - NMI Holdings' shares have returned -10.4% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3.6% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Merck (MRK) reported Q2 2025 adjusted EPS of $2.13, exceeding estimates, but a 7% decline year-over-year on a reported basis due to a $200 million upfront payment for a license agreement with Hengrui Pharma [2][9][17] - Revenues decreased 2% year-over-year to $15.81 billion, aligning with consensus estimates [3][9] Sales Performance of Oncology Drugs - Keytruda sales reached $7.96 billion, a 9% increase, driven by strong uptake in various cancer indications, surpassing estimates [4][9] - Alliance revenues from Lynparza and Lenvima contributed positively, with Lynparza sales up 15% to $370 million and Lenvima revenues totaling $265 million, up 5% [5] Sales Performance of Other Key Products - HPV vaccine sales (Gardasil and Gardasil 9) fell 55% to $1.13 billion due to reduced demand in China, missing estimates [7] - Sales of other vaccines showed mixed results, with Vaxneuvance increasing 20% to $229 million, while Rotateq and Pneumovax 23 saw significant declines [8][10] Animal Health Segment - The Animal Health segment generated $1.65 billion in revenues, an 11% increase year-over-year, driven by higher demand and the inclusion of Elanco aqua business sales [12] Cost and Margin Discussion - Adjusted gross margin improved to 82.2%, up 130 basis points year-over-year, attributed to a favorable product mix [13] - Adjusted R&D spending rose 15% to $3.99 billion, influenced by the upfront payment to Hengrui Pharma and increased compensation costs [14] 2025 Guidance - Merck narrowed its 2025 revenue guidance to $64.3-$65.3 billion, reflecting a less negative currency impact [15] - Adjusted EPS guidance is now between $8.87 and $8.97, accounting for a revised negative impact from foreign exchange [16] Acquisition Plans - Merck announced plans to acquire Verona Pharma for approximately $10 billion, expected to close in Q4 2025, which will enhance its portfolio in chronic obstructive pulmonary disease [19]

Core Insights - Lear Corp. (LEA) reported Q2 2025 adjusted earnings per share of $3.47, exceeding the Zacks Consensus Estimate of $3.23, driven by strong performance in the Seating and E-Systems segments, although down from $3.60 in the same quarter last year [1][9] - Total revenues for the quarter were flat year-over-year at $6.03 billion, surpassing the Zacks Consensus Estimate of $5.89 billion [1][9] Segmental Performance - The Seating segment generated sales of $4.47 billion, slightly up from $4.45 billion year-over-year, and exceeded the Zacks Consensus Estimate of $4.37 billion. Adjusted segment earnings were $298.9 million, down from $302.1 million year-over-year but above the estimate of $276 million, with adjusted margins at 6.7% [2] - The E-Systems segment reported sales of $1.56 billion, a 0.6% decline year-over-year, but still above the Zacks Consensus Estimate of $1.52 billion. Adjusted earnings were $75.8 million, down from $82.2 million year-over-year, yet surpassing the estimate of $67 million, with adjusted margins at 4.9% [3] Performance by Region - North America sales decreased by 1.3% year-over-year to $2.52 billion, exceeding the Zacks Consensus Estimate of $2.44 billion [4] - Europe and Africa region sales fell by 0.39% year-over-year to $2.16 billion, beating the Zacks Consensus Estimate of $2.13 billion [4] - Asia region sales increased by 6.5% year-over-year to $1.14 billion, surpassing the Zacks Consensus Estimate of $1.13 billion [4] Financial Position & Other Tidbits - As of June 28, 2025, the company had $888 million in cash and cash equivalents, down from $1.05 billion at the end of 2024. Long-term debt increased to $2.76 billion [6] - Net cash used in operating activities for the quarter was $296.2 million, with a free cash flow (FCF) of $170.8 million [6] - During the quarter, Lear repurchased 271,117 shares for a total of $25 million, with nearly $1 billion remaining in share repurchase authorization [7] 2025 Guidance - Lear projects full-year net sales between $22.47 billion and $23.07 billion, with core operating earnings expected in the range of $955 million to $1,095 million. Operating cash flow is anticipated to be between $1.01 billion and $1.11 billion, with FCF projected between $420 million and $520 million and capital spending estimated at $590 million [9][10]